Which hedge funds own BMRN? BIOMARIN PHARMACEUTICAL INC, Q2 2026 13F holders
Healthcare · Open on the interactive board
9 of the hedge funds tracked by WhaleCreep disclosed a position in BMRN (BIOMARIN PHARMACEUTICAL INC) in their Q2 2026 13F filings, worth $673.0m in total. The largest holder by portfolio weight is Viking Global Investors at 1.2% of its book. 1 manager opened a new position this quarter: Marshall Wace. 3 exited: Brevan Howard Capital Management, Point72 Asset Management LP, Rubric Capital Management.
9tracked managers holding
1opened this quarter
3exited this quarter
Which hedge funds hold BMRN? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Viking Global Investors | Q2 2026 | 1.2% | $435.8m | 7,616,563 | 8% | added |
| Millennium Management | Q2 2026 | 0.1% | $118.5m | 2,071,816 | -31% | reduced |
| Bridgewater Associates | Q2 2026 | 0.1% | $15.7m | 274,911 | 33% | added |
| Citadel Advisors | Q2 2026 | 0.0% | $64.2m | 1,122,408 | -75% | reduced |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $25.9m | 451,871 | -56% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $5.6m | 97,300 | – | new |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $5.3m | 92,214 | -67% | reduced |
| WCM Investment Management | Q2 2026 | 0.0% | $1.3m | 22,930 | 22% | added |
| Holocene Advisors | Q2 2026 | 0.0% | $668.3k | 11,679 | 0% | held |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Brevan Howard Capital Management | 0.0% | $562.3k |
| Point72 Asset Management LP | 1.5% | $67.7m |
| Rubric Capital Management | 3.9% | $24.9m |
How has hedge fund ownership of BMRN changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 9 | $673.0m |
| Q1 2026 | 11 | $1.0bn |
| Q4 2025 | 10 | $514.7m |
| Q3 2025 | 6 | $574.5m |
| Q2 2025 | 7 | $791.5m |
| Q1 2025 | 9 | $1.1bn |
| Q4 2024 | 8 | $994.8m |
| Q3 2024 | 10 | $1.1bn |
| Q2 2024 | 10 | $989.2m |
| Q1 2024 | 10 | $1.1bn |
| Q4 2023 | 9 | $918.3m |
| Q3 2023 | 5 | $456.2m |
| Q2 2023 | 6 | $471.2m |
| Q1 2023 | 7 | $339.5m |
| Q4 2022 | 10 | $729.7m |
| Q3 2022 | 11 | $645.4m |
Counts every tracked manager that disclosed BMRN in that quarter's filing, including managers that have since stopped filing.